Session: 701. Experimental Transplantation: Basic and Translational: Poster II
Hematology Disease Topics & Pathways:
hematopoiesis, immunology, Biological Processes
Results: We conducted single-cell multiomic RNA and ATAC sequencing of young and old HSCs defined by Lineage-CD34-CD48-CD150+Sca-1+Kit+. We identified two CD117 (Kit) HSC subsets, Kitlo and Kithi, with unique transcriptional profiles. Kithi HSCs were characterized by quiescence, platelet bias, and low-output gene signatures, while Kitlo HSCs enriched for multi-lineage and high-output gene signatures. We observed a decreased frequency of Kitlo HSCs in aged mice. Although Kitlo HSCs have been previously described to exhibit increased self-renewal (Shin et al. JEM, 2014), their T-cell potential and the molecular underpinnings governing lymphoid differentiation programs are unknown.
We performed in vitro studies, S17 stromal assay, and artificial thymic organoids (ATOs), which revealed an enhanced output of lymphoid progenitors and T-cells from Kitlo HSCs, consistent across all age cohorts. We next compared Kitlo vs. Kithi HSCs in a competitive allogeneic HCT model. Kitlo HSCs demonstrated improved thymic recovery and post-HCT T-cell reconstitution, independent of age. To orthogonally evaluate post-HCT thymic function, we assessed Recent Thymic Emigrants (RTEs) output, which further substantiated superior recovery in mice receiving Kitlo HSCs. We further observed that Kitlo HSC-derived T-cells exhibited better proliferation in response to an acute Listeria monocytogenes infection. Next, we transplanted middle-aged mice to evaluate the rejuvenation potential of different Kit HSC subsets. We observed that Kitlo HSCs partly mitigated age-related changes in the thymic microenvironment, specifically by enhancing the regeneration of thymic epithelial cells (TECs) in middle-aged mice, thereby reversing the decline in T-cell production.
We found differential expression and activity of key transcription factors (TFs), including Runx3, Zbtb7a, and Ezh1, associated with lymphoid differentiation through integrative transcriptional and chromatin accessibility analyses of Kitlo HSCs. These TFs notably showed distinct patterns in Kitlo HSCs independent of age, indicating their potential role in driving their enhanced T-cell potential.
To establish the existence of a comparable human subset, we interrogated a human BM CITE-Seq dataset (Sommarin et al. Biorxiv 2021) for the mouse Kitlo gene signature. In concordance with our findings in mice, we observed an enrichment of the Kitlo gene program in young HSCs and decreased frequency of Kitlo HSCs in old BM. Next, we used ATOs to validate differential lymphoid potential. We found increased T-cell output originating from Kitlo HSCs, thus underscoring their enhanced lymphoid capacity and potential clinical relevance.
Conclusion: Collectively, we demonstrate a distinct HSC subset, Kitlo HSC, with an age-conserved lymphoid gene program that enhances T-cell production and facilitates thymic regeneration. Importantly, we demonstrate the presence of an analogous HSC subset in humans, revealing the relevance of these insights to human health and disease. Thus, Kitlo HSCs have therapeutic potential to counteract age-associated immune senescence and treatment-related immune suppression.
Disclosures: Leslie: Episteme Prognostics,: Other: SAB member and co-inventor of IP. van den Brink: Seres Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: IP licensing , Research Funding; Rheos Medicines: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Frazier Healthcare Partners: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Notch Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ceramedix: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lygenesis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pluto Immunotherapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; DKMS (a non-profit organization): Membership on an entity's Board of Directors or advisory committees; Juno Therapeutics: Other: IP licensing; Wolters Kluwer: Patents & Royalties; Vor Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Da Volterra: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Thymofox: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
See more of: Oral and Poster Abstracts